News | October 31, 2022
Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The main objective of successive rounds of the NFHS is to provide reliable and comparable data relating to health and family welfare and other emerging issues
The initiative will engage adolescents and youth of India in decisions about their reproductive health
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Sales reflect continued strong growth in oncology and vaccines
International Business is expected to register double-digit growth in constant currency terms
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)